When was VISEN Pharmaceuticals founded?

VISEN Pharmaceuticals was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is VISEN Pharmaceuticals located?

VISEN Pharmaceuticals is headquartered in Shanghai, China. It is registered at Daugavpils, Arodu iela 23.

Which legal entities is VISEN Pharmaceuticals associated with?

VISEN Pharmaceuticals is associated with VISEN.

How many employees does VISEN Pharmaceuticals have?

As of Jul 01, 2024, the latest employee count at VISEN Pharmaceuticals is 51 - 200.

Is VISEN Pharmaceuticals a funded company?

VISEN Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jan 08, 2021.

When was the latest funding round of VISEN Pharmaceuticals?

VISEN Pharmaceuticals' latest funding was a $***** Series B round on Jan 08, 2021, with participation from 10 investors. Its primary sector is Metabolic Diseases. In China, the Metabolic Diseases sector has seen $370M in funding in 2026 to date.

Where does VISEN Pharmaceuticals rank among its competitors?

VISEN Pharmaceuticals ranks 19th amongst 60 active competitors, of which 16 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was GRIN Therapeutics, which secured $140M in May, 2025.

Who are the top competitors of VISEN Pharmaceuticals?

VISEN Pharmaceuticals' top competitors include Crinetics, Ironwood Pharma and Neurocrine. Among them, GRIN Therapeutics secured the most recent funding round in May, 2025.

VISEN Pharmaceuticals - 2026 Company Profile, Funding & Competitors

VISEN Pharmaceuticals is a public company based in Shanghai (China), founded in 2018. It operates as a Provider of therapeutics solution for endocrine-related diseases. VISEN Pharmaceuticals has raised $150M in funding from Sequoia Capital. The company has 60 active competitors, including 16 funded and 20 that have exited. Its top competitors include companies like Crinetics, Ironwood Pharma and Neurocrine.

Company Details

Provider of therapeutics solution for endocrine-related diseases. The company proprietary drugs include TransCon hGH which is used as Pediatric Growth Hormone Deficiency (PGHD) and used for impaired or secretion of Human Growth Hormone (hGH) in the child. TransCon PTH Hypoparathyroidism (HP) is used as a congenital HP and acquired HP, used for damage or accidental removal of the parathyroid glands. TransCon CNP used as Achondroplasia (ACH) which is used in dwarfism. The company uses the proprietary technology TransCon platform for transient conjugation.

Website: visenpharma.com/cn
Email ID: *****@visenpharma.com
Phone Number: +86 **********
Registered Address: Daugavpils, Arodu iela 23

Key Metrics

Founded Year

2018

Location

Shanghai, China

Stage

Public

Total Funding

$150M in 1 round

Latest Funding Round

Series B, Jan 08, 2021, $*****

Investors

Sequoia Capital & 12 more

Ranked

19^th among 60 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

Crinetics & 72 more

Exit Details

Public

View VISEN Pharmaceuticals' full profile

VISEN Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VISEN CIN: 41503059268 , Latvia, Active	Apr 02, 2012	€0 - €1M (As on Dec 31, 2022)	3 (As on Dec 31, 2022)	-

VISEN Pharmaceuticals got listed on Mar 21, 2025.

Click here to take a look at VISEN Pharmaceuticals's IPO in detail

VISEN Pharmaceuticals has raised a total funding of $150M over 1 round. Its latest funding round was a Series B round on Jan 08, 2021 for $*****. 10 investors participated in its latest round. VISEN Pharmaceuticals has 13 institutional investors.

Here is the list of recent funding rounds of VISEN Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2021	6860307	Series B	5889789	3360569	8646509	4453628

Access funding benchmarks and valuations. Sign up today!

View details of VISEN Pharmaceuticals's funding rounds and investors

VISEN Pharmaceuticals' employee count trend

VISEN Pharmaceuticals has 51 - 200 employees as of Jul 24. Here is VISEN Pharmaceuticals's employee count trend over the years:

Employee count trend for VISEN Pharmaceuticals

Uncover VISEN Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VISEN Pharmaceuticals include Crinetics, Ironwood Pharma and Neurocrine. Here is the list of Top 10 competitors of VISEN Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Crinetics 2008, San Diego (United States), Acquired	Developer of therapies for the treatment of endocrine-related diseases and cancers	$104M	Perceptive Advisors, Vivo Capital & 12 others	69/100
2nd	Ironwood Pharma 1998, Cambridge (United States), Public	Developer of therapeutics for gastrointestinal disorders	$206M	Athyrium Capital Management, F-Prime Capital ... & 15 others	68/100
3rd	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	BB Biotech, Avalon Ventures & 5 others	68/100
4th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, SVB & 5 others	65/100
5th	Sigilon 2015, Cambridge (United States), Acquired	Developer of therapeutics to treat chronic diseases	$104M	CPP Investments, BlackRock & 5 others	55/100
6th	Laminar Pharma 2006, Palma (Spain), Series A	Developer of melipathy based drugs	$14.7M	Fundacionalbaperez, Matutes family & 3 others	54/100
7th	Lipum 2010, Umea (Sweden), Public	Developer of antibody to treat juvenile idiopathic arthritis	$2.99M	Almi Invest, Flerie & 2 others	54/100
8th	Clarus Therapeutics 2003, Northbrook (United States), Public	Oral testosterone replacement therapy.	$39.5M	H.I.G. Capital, HIG BioHealth Partners & 4 others	53/100
9th	ORPHELIA Pharma 2007, Paris (France), Acquired	Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology	$4.49M	Initiative OCTALFA, Bpifrance & 1 others	52/100
10th	GRIN Therapeutics 2021, United States, Series D	Developing precision therapeutics for pediatric neurodevelopmental disorders	$140M	Blackstone, Angelini Pharma	50/100
19th	VISEN Pharmaceuticals 2018, Shanghai (China), Public	Provider of therapeutics solution for endocrine-related diseases	$150M	Orbimed, CDG Capital & 11 others	42/100